Channing Capital Management’s Pfizer PFE Stock Holding History

Channing Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-224,404	Closed	-$7.71M	–	110
2017 Q4	$7.71M	Sell	224,404 -5,550	-2%	-$189K	0.26%	82
2017 Q3	$7.79M	Buy	229,954 +7,935	+4%	+$255K	0.29%	80
2017 Q2	$7.08M	Sell	222,019 -3,180	-1%	-$100K	0.28%	80
2017 Q1	$7.31M	Hold	225,199	–	–	0.27%	79
2016 Q4	$6.94M	Sell	225,199 -46,070	-17%	-$1.41M	0.25%	80
2016 Q3	$8.72M	Hold	271,269	–	–	0.35%	72
2016 Q2	$9.06M	Buy	271,269 +64,641	+31%	+$2.06M	0.38%	66
2016 Q1	$5.81M	Buy	+206,628	New	+$5.9M	0.26%	80

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Channing Capital Management's PFE Position: Q1 2018 in Review

Channing Capital Management sold out of Pfizer (PFE) in Q1 2018, closing a stake of 224,404 shares — an estimated $7.71M sold.

Channing Capital Management first reported a position in PFE in Q1 2016 and held it in 8 quarters. The position peaked at $9.06M in Q2 2016. 2,229 funds tracked by Wall St. Rank hold PFE as of Q1 2018.

Channing Capital Management reported no remaining Pfizer position as of Q1 2018 after selling out during the quarter.
Channing Capital Management sold 224,404 Pfizer shares in Q1 2018, an estimated $7.71M.
Channing Capital Management first reported a position in Pfizer in Q1 2016 and held it in 8 quarters.
Channing Capital Management's Pfizer position peaked at $9.06M in Q2 2016.
2,229 funds tracked by Wall St. Rank held Pfizer as of Q1 2018.

Based on Channing Capital Management's 13F filing for Q1 2018, filed 24 Apr 2018.